Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

(2017) R T Swords et al.   Blood Cancer Journal

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

(2016) Shailender Bhatia et al.   INVESTIGATIONAL NEW DRUGS

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

(2015) Ronan T. Swords et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

(2015) J. J. Shah et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

(2015) J. Sarantopoulos et al.   CLINICAL CANCER RESEARCH

Abstract B148: Population pharmacokinetics (PK) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) administered alone or in combination with azacitidine in patients (pts) with solid or hematologic malignancies

(2015) Hélène M. Faessel et al.   MOLECULAR CANCER THERAPEUTICS

Abstract C55: Nedd8-activating enzyme inhibitor pevonedistat synergizes with cisplatin and carboplatin through interference with nucleotide excision repair and interstrand cross-link repair mechanisms in non-small cell lung cancer

(2015) David C. Bouck et al.   MOLECULAR CANCER THERAPEUTICS

Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways

(2014) K. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody

(2014) David Hersi Smith et al.   Scientific Reports

ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer

(2013) Shan Li et al.   ANTI-CANCER DRUGS

Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer

(2013) S. T. Nawrocki et al.   CLINICAL CANCER RESEARCH

Cullin-RING Ligases as Attractive Anti-cancer Targets

(2013) Yongchao Zhao et al.   CURRENT PHARMACEUTICAL DESIGN

DNA repair mechanisms in dividing and non-dividing cells

(2013) Teruaki Iyama et al.   DNA REPAIR

Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924

(2013) A. A. Jazaeri et al.   MOLECULAR CANCER THERAPEUTICS

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

(2013) Luc Friboulet et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

(2012) Z. Luo et al.   CANCER RESEARCH

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

(2010) Sufeng Chen et al.   LUNG CANCER

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

(2010) James E. Brownell et al.   MOLECULAR CELL

Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer

(2009) T. A. Soucy et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER